"Excelera’s model of health-system based specialty pharmacies, integrated at the point of patient care, is ideal for ensuring appropriate utilization of these limited distribution therapies with the highest standards of quality and safety."
Minneapolis, MINN (PRWEB) February 25, 2015
ExceleraRx Corp. announced today that it has been selected as part of Pfizer Inc.'s limited-distribution network for a suite of its products including: Bosulif® (bosutinib), Ibrance® (palbociclib), Inlyta® (axitinib), Sutent® (sunitinib malate) and Xalkori® (crizotinib).
"We are proud to be included in Pfizer's limited-distribution network for these five important treatments," said Jim Fox, Chief Executive Officer of the Excelera Network. "Excelera’s model of health-system based specialty pharmacies, integrated at the point of patient care, is ideal for ensuring appropriate utilization of these limited distribution therapies with the highest standards of quality and safety."
“We are excited that the Excelera network has access to these important treatments,” said Albert “Bert” Zimmerli, ExceleraRx Corp. Board Chair and Executive Vice President and Chief Financial Officer, Intermountain Healthcare. “This enables Intermountain Healthcare and other member health systems to maintain the highest standards of care for patients needing these crucial medications.”
ExceleraRx Corp., a national network of specialty pharmacies based at health systems and academic medical centers, enables member organizations to gain access to limited distribution drugs and restricted payer agreements. The Excelera network provides national-scale efficiency and collaboration to improve quality and value of outpatient specialty drug therapy for population health outcomes. Excelera’s mission is to “provide tools, technology and best practices around high-performing specialty pharmacy capabilities to network members so that they can provide integrated, coordinated care to complex patients at the point of care leading to improved health outcomes and decreased healthcare costs.” For more information about Excelera, visit http://www.excelerarx.com.